Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Next Previous
X
Search
Trial Profile

A Randomized, Open-label, Phase 2 Trial of Sipuleucel-T With Concurrent Versus Sequential Administration of Abiraterone Acetate Plus Prednisone in Men With Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sipuleucel-T (Primary) ; Abiraterone acetate; Prednisone
  • Indications Prostate cancer
  • Focus Pharmacodynamics
  • Acronyms STAMP
  • Sponsors Dendreon Corporation

    • Most Recent Events

    • 25 Feb 2021 Results for analyses of T cells from sipuleucel-T-treated subjects in STAMP showing direct lysis of cells that express prostate cancer target antigens through video recordings, published in the Journal of the National Cancer Institute
    • 15 Feb 2020 Results assessing association of humoral antigen spread with cytotoxic T lymphocyte activity after sipuleucel-T treatment in two studies (STAMP and STRIDE), presented at the 2020 Genitourinary Cancers Symposium.
    • 13 Feb 2020 Results published in the Dendreon corporation media release

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top